Data for: A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer
收藏doi.org2025-01-22 收录
下载链接：
http://doi.org/10.17632/yj4byrkjmj.1
下载链接
链接失效反馈官方服务：
资源简介：
Protocol and SAP
协议与SAP
提供机构：
doi.org
